SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that Michael Morrissey, Ph.D., the company's president of research and development, will present at the 2007 BIO InvestorForum conference at 2:45 p.m. (PDT) / 5:45 p.m. (EDT) on Wednesday, October 10, 2007.
The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.
CONTACT: Charles Butler, Director, Investor Relations, +1-650-837-7277,
cbutler@exelixis.com, or Hal Mackins, +1-650-837-7012,
hmackins@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com/
